QSAR modeling for the prediction of pGI50 activity of compounds on LOX IMVI cell line and ligand-based design of potent compounds using in silico virtual screening

  • Bello Abdullahi UmarEmail author
  • Adamu Uzairu
  • Gideon Adamu Shallangwa
  • Uba Sani
Original Article


The anti-melanoma activity (pGI50) values of 71 compounds from the National Cancer Institute (NCI) data bank on LOX IMVI cell line were modeled to illustrate the Quantitative structure–activity relationship (QSAR) of the compounds. The genetic function algorithm (GFA) has been used to select the most relevant descriptors so as to improve the performance of the QSAR model. The statistical significance of the model was verified based on the values of validation parameters such as \( R_{{{\text{train}} }}^{2} \) (0.867), \( R_{{{\text{adj}} }}^{2} \) (0.848), \( Q_{{{\text{cv}} }}^{2} \) (0.809) and \( R_{{{\text{test}} }}^{2} \) (0.749) needed to evaluate the robustness and strength of the model. The result of the internal and external validation of the model indicates that the model is good and could be used to predict pGI50 of anti-melanoma compounds on LOX IMVI cell line for which no experimental data are available. Compound 41 was selected using in-silico screening method as a template due to its good pGI50 (9.793) and was utilized to design new potent compounds, thereby enhancing the activity of the parent structure. Ten (10) new potent compounds were deigned and predicted using the proposed model. The predicted pGI50 of the majority of the designed analogous were more than the lead compound 41 used for the design and among which compound N5 showed the best activity (pGI50=13.186). Thus, this study provides a valuable approach and new direction to novel drug discovery.


LOX IMVI cell line NCI Anti-melanoma GFA-MLR QSAR Williams plot 



The authors sincerely acknowledge Ahmadu Bello University, Zaria for providing the softwares used and all the members of the group for their advice and encouragement in the cause of this research.


The authors received no direct funding for this research.

Compliance with ethical standards

Conflict of interest

The authors have declared they have no conflict of interest.

Human and animal rights statement

This article does not contain any studies with human or animal subjects.


  1. Abdulfatai U, Uzairu A, Uba S (2017) Quantitative structure-activity relationship and molecular docking studies of a series of quinazolinonyl analogues as inhibitors of gamma amino butyric acid aminotransferase. J Adv Res 8(1):33–43CrossRefGoogle Scholar
  2. Al-Suwaidan IA, Abdel-Aziz AA-M, Shawer TZ, Ayyad RR, Alanazi AM, El-Morsy AM, Mohamed MA, Abdel-Aziz NI, El-Sayed MA-A, El-Azab AS (2016) Synthesis, antitumor activity and molecular docking study of some novel 3-benzyl-4 (3H) quinazolinone analogues. J Enzyme Inhib Med Chem 31(1):78–89CrossRefGoogle Scholar
  3. Amin SA, Gayen S (2016) Modelling the cytotoxic activity of pyrazolo-triazole hybrids using descriptors calculated from the open source tool “PaDEL-descriptor”. J Taibah Univ Sci 10(6):896–905CrossRefGoogle Scholar
  4. Anderson CM, Buzaid AC, Legha SS (1995) Systemic treatments for advanced cutaneous melanoma. Oncology 9:4–5Google Scholar
  5. Arthur DE, Uzairu A, Mamza P, Abechi S (2016) Quantitative structure–activity relationship study on potent anticancer compounds against MOLT-4 and P388 leukemia cell lines. J Adv Res 7(5):823–837CrossRefGoogle Scholar
  6. Asadollahi T, Dadfarnia S, Shabani AMH, Ghasemi JB, Sarkhosh M (2011) QSAR models for CXCR6 receptor antagonists based on the genetic algorithm for data preprocessing prior to application of the PLS linear regression method and design of the new compounds using in silico virtual screening. Molecules 16(3):1928–1955CrossRefGoogle Scholar
  7. Barth A, Wanek LA, Morton DL (1995) Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 181(3):193–201Google Scholar
  8. Chabner BA (1990) Cancer chemotherapy: principles and practice. Lippincott Williams and Wilkins, United States, pp 341–355Google Scholar
  9. Choi W-K, El-Gamal MI, Choi HS, Baek D, Oh C-H (2011) New diarylureas and diarylamides containing 1, 3, 4-triarylpyrazole scaffold: synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies. Eur J Med Chem 46(12):5754–5762CrossRefGoogle Scholar
  10. Eriksson L, Jaworska J, Worth AP, Cronin MT, McDowell RM, Gramatica P (2003) Methods for reliability and uncertainty assessment and for applicability evaluations of classification-and regression-based QSARs. Environ Health Perspect 111(10):1361–1375CrossRefGoogle Scholar
  11. Gramatica P, Giani E, Papa E (2007) Statistical external validation and consensus modeling: a QSPR case study for Koc prediction. J Mol Graph Model 25(6):755–766CrossRefGoogle Scholar
  12. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445(7130):851CrossRefGoogle Scholar
  13. Hehre W, Huang W (1995) Chemistry with computation: an introduction to SPARTAN. Wavefunction. Inc, Irvine, CAGoogle Scholar
  14. Jalali-Heravi M, Konuze E (2002) Use of quantitative structure property relationships in predicting the kraft point of anionic surfactants. Electron J Mol Des 1:410–417Google Scholar
  15. Jaworska J, Nikolova-Jeliazkova N, Aldenberg T (2005) QSAR applicability domain estimation by projection of the training set descriptor space: a review. Atla-Nottingham 33:445Google Scholar
  16. Kennard RW, Stone LA (1969) Computer aided design of experiments. Technometrics 11(1):137–148CrossRefGoogle Scholar
  17. Leardi R (1996) Genetic algorithms in molecular modeling. Elsevier, pp 67–86Google Scholar
  18. Lee JA, Roh EJ, Oh C-H, Lee SH, Sim T, Kim JS, Yoo KH (2015) Synthesis of quinolinylaminopyrimidines and quinazolinylmethylaminopyrimidines with antiproliferative activity against melanoma cell line. J Enzyme Inhib Med Chem 30(4):607–614CrossRefGoogle Scholar
  19. Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64(2):327–336CrossRefGoogle Scholar
  20. Makrariya A, Pardasani K (2019) Numerical study of the effect of non-uniformly perfused tumor on heat transfer in women’s breast during menstrual cycle under cold environment. Netw Modeling Anal Health Inform Bioinform 8(1):9CrossRefGoogle Scholar
  21. Melagraki G, Afantitis A, Sarimveis H, Koutentis PA, Markopoulos J, Igglessi-Markopoulou O (2007) Optimization of biaryl piperidine and 4-amino-2-biarylurea MCH1 receptor antagonists using QSAR modeling, classification techniques and virtual screening. J Comput Aided Mol Des 21(5):251–267CrossRefGoogle Scholar
  22. Melagraki G, Afantitis A, Sarimveis H, Koutentis PA, Kollias G, Igglessi-Markopoulou O (2009) Predictive QSAR workflow for the in silico identification and screening of novel HDAC inhibitors. Mol Divers 13(3):301–311CrossRefGoogle Scholar
  23. Mignatti P, Rifkin DB (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73(1):161–195CrossRefGoogle Scholar
  24. Muegge I, Oloff S (2006) Advances in virtual screening. Drug Discov Today Technol 3(4):405–411CrossRefGoogle Scholar
  25. Naik PA, Pardasani KR (2018) 2D finite-element analysis of calcium distribution in oocytes. Netw Model Anal Health Inform Bioinform 7(1):10CrossRefGoogle Scholar
  26. Rajer-Kanduč K, Zupan J, Majcen N (2003) Separation of data on the training and test set for modelling: a case study for modelling of five colour properties of a white pigment. Chemom Intell Lab Syst 65(2):221–229CrossRefGoogle Scholar
  27. Roskoski R (2012) MEK1/2 dual-specificity protein kinases: structure and regulation. Biochem Biophys Res Commun 417(1):5–10CrossRefGoogle Scholar
  28. Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE, Piccart-Gebhart MJ (2013) Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev 39(8):935–946CrossRefGoogle Scholar
  29. Tropsha A, Gramatica P, Gombar VK (2003) The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. Mol Inform 22(1):69–77Google Scholar
  30. Vaidya A, Jain S, Jain S, Jain AK, Agrawal RK (2014) Quantitative structure-activity relationships: a novel approach of drug design and discovery. J Pharm Sci Pharmacol 1(3):219–232CrossRefGoogle Scholar
  31. Viswanadhan VN, Ghose AK, Revankar GR, Robins RK (1989) Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J Chem Inf Comput Sci 29(3):163–172CrossRefGoogle Scholar
  32. Wu C-P, Ambudkar SV (2014) The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy. Acta Pharm Sin B 4(2):105–111CrossRefGoogle Scholar
  33. Wu W, Zhang C, Lin W, Chen Q, Guo X, Qian Y, Zhang L (2015) Quantitative structure-property relationship (QSPR) modeling of drug-loaded polymeric micelles via genetic function approximation. PLoS One 10(3):e0119575CrossRefGoogle Scholar
  34. Yap CW (2011) PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints. J Comput Chem 32(7):1466–1474MathSciNetCrossRefGoogle Scholar
  35. Young D (2004) Computational chemistry: a practical guide for applying techniques to real world problems. Wiley, Hoboken, New Jersey, United StatesGoogle Scholar
  36. Zubrilov I, Sagi-Assif O, Izraely S, Meshel T, Ben-Menahem S, Ginat R, Pasmanik-Chor M, Nahmias C, Couraud P-O, Hoon DS (2015) Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells. Cancer Lett 361(1):86–96CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  • Bello Abdullahi Umar
    • 1
    Email author
  • Adamu Uzairu
    • 1
  • Gideon Adamu Shallangwa
    • 1
  • Uba Sani
    • 1
  1. 1.Department of Chemistry, Faculty of Physical SciencesAhmad Bello UniversityZariaNigeria

Personalised recommendations